Background: Two approaches are available for measuring Alzheimer's disease (AD)
pathology in vivo. Biomarkers in cerebrospinal fluid (CSF) include amyloid-β 1-42 (Aβ 42) …

Differential diagnosis of AD is still a challenge due to overlapping features with other types
of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value …

The diagnostic performances of cerebrospinal fluid (CSF) biomarkers and amyloid positron
emission tomography (PET) were compared by examining the association and concordance …

A growing body of evidence suggests that Alzheimer's disease (AD) is a multifactorial
disease resulting in the well-known, common neuropathological pathway characterized by …

It is currently unclear whether plasma biomarkers can be used as independent prognostic
tools to predict changes associated with early Alzheimer's disease. In this study, we sought …

INTRODUCTION We set out to identify tau PET‐positive (A+ T+) individuals among amyloid‐
beta (Aβ) positive participants using plasma biomarkers. METHODS In this cross‐sectional …

Introduction We sought to establish the relationships between standard postmortem
measures of AD neuropathology and antemortem [11 C] PIB–positron emission tomography …

Introduction The aim of this study is to investigate the role of plasma phosphorylated tau (p-
tau) 181 as a potential biomarker for Alzheimer's Disease (AD) pathology in the early stages …

Introduction Direct comparisons of the main blood phosphorylated tau immunoassays in
memory clinic populations are needed to understand possible differences. Methods In the …

Background Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate
biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are …